角膜移植随访研究II:HLA II类匹配不能降低穿透性角膜移植排斥风险
这项随机试验纳入1133例穿透性角膜移植,在HLA I类抗原匹配(A、B位点≤2个错配)基础上,按队列最小化分配至HLA II类抗原0、1或2个错配,随访5年。Cox回归显示HLA II类错配与排斥风险无关(HR 1.13;95%CI 0.79-1.63;p=0.51)。受体年龄>60岁排斥风险较≤40岁减半(HR 0.51;95%CI 0.36-0.73;p=0.0003),PK后白内障手术(HR 3.68;95%CI 1.95-6.93;p<0.0001)及≥2个术前危险因素(HR 2.11;95%CI 1.26-3.47;p<0.003)增加排斥风险。
要点
- HLA II类匹配在HLA I类匹配背景下未降低排斥风险(HR 1.13;p=0.51)。
- 受体年龄>60岁排斥风险较≤40岁减半(HR 0.51;p=0.0003)。
- PK后白内障手术及≥2个术前危险因素显著增加排斥风险。
核心结论
- HLA II类匹配在HLA I类匹配背景下未降低穿透性角膜移植排斥风险。
- 年轻受体、≥2个术前危险因素及PK后白内障手术显著增加排斥风险。
研究设计与样本
- 随机对照试验,1133例穿透性角膜移植,HLA I类抗原匹配(A、B位点≤2个错配),按队列最小化分配至HLA II类抗原0、1或2个错配,随访5年。
主要发现
- HLA II类错配与免疫排斥风险无关(HR 1.13;95%CI 0.79-1.63;p=0.51)。
- 受体年龄>60岁较≤40岁排斥风险减半(HR 0.51;95%CI 0.36-0.73;p=0.0003)。
- PK后白内障手术增加排斥风险(HR 3.68;95%CI 1.95-6.93;p<0.0001)。
- 单因素分析中慢性青光眼(p=0.02)、血管化(p=0.01)、炎症(p=0.03)、眼表疾病(p=0.0007)及再移植(p<0.001)增加排斥风险,但Cox模型中均不独立显著。
- Cox模型中≥2个术前危险因素增加排斥风险(HR 2.11;95%CI 1.26-3.47;p<0.003)。
关键数值与推荐
- HLA I类抗原匹配标准:A、B位点≤2个错配。
- HLA II类抗原错配分组:0、1或2个错配。
- 主要结局:首次排斥时间。
临床怎么用
- 在高风险穿透性角膜移植中,不必为降低排斥而常规进行HLA II类匹配。
- 应关注年轻受体、≥2个术前危险因素及PK后白内障手术等排斥高危因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: A randomised trial to test the hypothesis that human leucocyte antigen (HLA) class II matching reduces the risk of allograft rejection in high-risk penetrating keratoplasty (PK). METHODS: All transplants were matched for HLA class I antigens (≤2 mismatches at the A and B loci) and corneas were allocated to patients by cohort minimisation to achieve 0, 1 or 2 HLA class II antigen mismatches. The corneal transplants (n=1133) were followed for 5 years. The primary outcome measure was time to first rejection episode. RESULTS: Cox regression analysis found no influence of HLA class II mismatching on risk of immunological rejection (HR 1.13; 95% CI 0.79 to 1.63; p=0.51). The risk of rejection in recipients older than 60 years was halved compared with recipients ≤40 years (HR 0.51; 95% CI 0.36 to 0.73; p=0.0003). Rejection was also more likely where cataract surgery had been performed after PK (HR 3.68; 95% CI 1.95 to 6.93; p<0.0001). In univariate analyses, preoperative factors including chronic glaucoma (p=0.02), vascularisation (p=0.01), inflammation (p=0.03), ocular surface disease (p=0.0007) and regrafts (p<0.001) all increased the risk of rejection. In the Cox model, however, none of these factors was individually significant but rejection was more likely where≥2 preoperative risk factors were present (HR 2.11; 95% CI 1.26 to 3.47; p<0.003). CONCLUSIONS: HLA class II matching, against a background of HLA class I matching, did not reduce the risk of allograft rejection. Younger recipient age, the presence of ≥2 preoperative risk factors and cataract surgery after PK all markedly increased the risk of allograft rejection. TRIAL REGISTRATION NUMBER: ISRCTN25094892.
引用
- Armitage WJ, Winton HL, Jones MNA, et al. Corneal Transplant Follow-up Study II: a randomised trial to determine whether HLA class II matching reduces the risk of allograft rejection in penetrating keratoplasty. Br J Ophthalmol. 2020. PMID: 33268345. doi:10.1136/bjophthalmol-2020-317543
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。